The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

Peer review reports

Original Submission
1 May 2021	Submitted	Original manuscript
4 May 2021	Reviewed	Reviewer Report - Kirsty Loudon
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
6 May 2021	Editorially accepted
25 May 2021	Article published	10.1186/s13063-021-05316-3

Back to article page